Scripps Family Affirms Control, Ratifies Poison Pill, and Continues Share Purchases Amidst Financial Challenges

summarizeSummary

The Scripps family, a controlling shareholder group, will vote to ratify the company's shareholder rights plan and made approximately $2.2 million in open market share purchases, signaling confidence despite recent financial challenges.

check_boxKey Events

• Scripps Family to Ratify Shareholder Rights Plan

  The Reporting Persons, comprising the Scripps family, have voted to ratify the company's shareholder rights plan (poison pill) at the 2026 annual meeting. This plan, adopted in November 2025, is a defensive measure to protect against hostile takeovers and will expire in November 2026 if ratified.

• Significant Insider Purchases by Scripps Family Members

  Multiple Scripps family members, who are Reporting Persons, collectively purchased approximately $2.2 million worth of Class A Common Shares in open market transactions between March 9-10, 2026. These purchases represent a significant investment by the controlling family.

• Director Establishes 10b5-1 Selling Plan

  Charles L. Barmonde, a director and Reporting Person, entered into a Rule 10b5-1 trading plan on March 11, 2026, to sell up to 40,000 Class A Common Shares between September 8, 2026, and September 8, 2027. This is a pre-planned, routine sale.

auto_awesomeAnalysis

This Schedule 13D/A filing reveals that the Scripps family, a controlling shareholder group, has collectively voted to ratify the company's shareholder rights plan (poison pill) at the upcoming 2026 annual meeting. This move, following the plan's adoption in November 2025, strengthens the board's defensive posture against potential hostile takeovers, especially in light of the company's recent substantial net loss and revenue decline. Concurrently, several Scripps family members made significant open market purchases totaling approximately $2.2 million in Class A Common Shares between March 9-10, 2026. These purchases, representing over 0.6% of the company's market capitalization, signal a notable vote of confidence from the controlling family amidst challenging financial results. Additionally, a director, Charles L. Barmonde, established a 10b5-1 plan to sell up to 40,000 shares, a routine pre-planned transaction with minor impact.